Rituximab carries high risks of hepatitis B virus reactivation in hematologic and rheumatic patients with chronic or resolved hepatitis B.

Kuan-Chu HouTung-Hung SuChien-Neng KaoHuei-Ru ChengTai-Chung TsengChun-Jen LiuSong-Chou HsiehJia-Horng Kao

Published in: Journal of gastroenterology and hepatology (2024)

Rituximab therapy is associated with a 50-64% risk of HBV reactivation regardless of underlying diseases and HBsAg status. HBV DNA levels should be assessed before initiating rituximab.

Keyphrases

hepatitis b virus
diffuse large b cell lymphoma
chronic lymphocytic leukemia
hodgkin lymphoma
liver failure
rheumatoid arthritis
circulating tumor
cell free
single molecule